{"name":"Contera Pharma","slug":"contera-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNTVo3TTNJTklsWXQ3RnlPN0lyTnBGZnJxOXl2UThYOUdzTzdVQno2ZV9mZGEydTFnM1p2ckVMVjh5TVUzTW9ra2I4djhFZWhRRXkwRzZhZ081eVNZbnNkam1zWl8xQlJFR0VmOE9WdmNnQ3NYUmdmLXkyOHh6bmFEX9IBlAFBVV95cUxQdm5lUjJkY2NicmxTQUdTSWk3aE04VTRTOU5PdVRETm9IckY4a2ZjY1hBaUhqUlUtUWZqdGhIZkkzODJpWXVreVdiT2ZNMWFCbWNDUC1Sd2xPMHNnWGJHZWdHa3lUTzByTERNdGd6eHZoN3pJTUp0LUxCU29jcVl3NF9lQlZqV1RaUzlfVUlxMy10RnlR?oc=5","date":"2026-03-25","type":"pipeline","source":"Chosunbiz","summary":"Bukwang Pharmaceutical accelerates expansion and R&D split to target Korea top 20 by 2030 - CHOSUNBIZ - Chosunbiz","headline":"Bukwang Pharmaceutical accelerates expansion and R&D split to target Korea top 20 by 2030 - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPY2R4ZGRMNndkUm5mMnd6cEJvaC1NTTd4T3BSNUpSNlAtSEw2WWNCTGs4elBEV2gxRTVaR21yLUVxS1J5cFZ5dHFOTzYtNzFkb0hoeXdGdThKM2FYNjdhMks5Q2dnWUs2N25jU19oQUZQQUQ3bDNTWmlSQ1F3dC1TadIBlAFBVV95cUxNSkJPblg3aGxQUnBRczlpRHlmVTRKY2tfWGU0TzlJRjQxMXBFZWIyYXVVUWFudXFOOEZaMHZpNlJhaG5VTXhUTTM3UnJ3Z1RCRHNZQzFfbE5uWUdKaURaRDcwVzhxNGRSUVRwSUYteTZmRDFxWXlOci13MFFnRzQxQXB6QmtQcHdvQWVud2tkdUluMXMy?oc=5","date":"2026-02-09","type":"earnings","source":"Chosunbiz","summary":"Bukwang Pharmaceutical surges on profit jump, R&D wins, and Korea acquisition - CHOSUNBIZ - Chosunbiz","headline":"Bukwang Pharmaceutical surges on profit jump, R&D wins, and Korea acquisition - CHOSUNBIZ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiQkFVX3lxTE9QdDRIcE9lUENtLUgyTUJKZ2E1SS1zX19NU2N0QzVYRHVWaExzUk94SkZSUV9tNkwxamFNQ0pkaFRBQQ?oc=5","date":"2025-11-18","type":"pipeline","source":"코메디닷컴","summary":"Bukwang Pharm: “Spinning Off Danish Subsidiary and Strengthening Momentum for RNA Therapeutics Development” - 코메디닷컴","headline":"Bukwang Pharm: “Spinning Off Danish Subsidiary and Strengthening Momentum for RNA Therapeutics Development” - 코메디닷컴","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNdmhUYS1RODJINE1pY1VaZWh5MnY0V2JXMDlVbXJuWk5WV1lkcVczaUc0VDlFRlVPNDJDQ05VajU4UXA2VE1kSlZNdXVXb1FMQnl3YkEtMktZbV9oS0V2bndULU5lUmNRam5aNi1uNEZnbTNaV0c2a0JMV0R2cnhwdk9PMmhYVFBjYXA5LWZwNk9sVXcwY3ptaXh6QQ?oc=5","date":"2025-10-21","type":"deal","source":"Pharmaceutical Technology","summary":"Lundbeck and Contera partner for oligonucleotide-based medicines - Pharmaceutical Technology","headline":"Lundbeck and Contera partner for oligonucleotide-based medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxONVU1MHhwcmRiRGxnc20ydk5yOTJKb191clpyd1VnT2tHeUh5cTAtbERCZnBIRUZZZTFnRFFLUzVqYTZZS3Z5cl9LdVVodUV4SkFuWGNkTVdZSEhNM1UxU3FRWE5EZm1CM1pSNk5IZGdUb1BabEU3R1RBeGZZX0hrUFpRNDlYVFVZY2JmZHhZLW9naXBQdE5NelpMckNhcVAyZExTMA?oc=5","date":"2025-10-21","type":"deal","source":"BioWorld News","summary":"Lundbeck and Contera Pharma partner in neurological disorders - BioWorld News","headline":"Lundbeck and Contera Pharma partner in neurological disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQkx4SzBaVXBXNENEblFWeFNwME1UYUdLVEczMG45a25HMWgyMEZJV0gwRm94M0w5NDk4Q2lKMGJHNEZrNEVSM0puLUV6ckZUUHRlN21ublc4OHhjSm95bDRhamJZWkhJYkhGX2hkb2VteDJhcFg3ekVQSG81bmt0MkRDWnJWZV9YQmM4OG5QTVRrdnlBOHVGUFlsdjA0S0ZBSFNZ?oc=5","date":"2025-10-21","type":"deal","source":"European Medical Journal","summary":"Lundbeck and Contera partner on RNA-targeted drug discovery - European Medical Journal","headline":"Lundbeck and Contera partner on RNA-targeted drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOZmhZSW5UOVdPOUZxRjMxal9iQjV2dmt3RzdzVlgxQnNEVlhSZTdrSDNzWWo4VnZ5ajBhYXVmM21na0ppczZ1eXNHNmVXZUhkdUQtM2ptQXFVbTNpd0VTRnM2aVdwcDN6c2NfbENCay16Z1VPSkxVTEo0WG1ZMElxdG4wZVZ1TlpnUXdEM0ZxYjkycjFpUDFQc0ZhS1V5TVkzdUVZ?oc=5","date":"2025-10-20","type":"deal","source":"European Biotechnology Magazine","summary":"Lundbeck inks licence option deal with Contera Pharma - European Biotechnology Magazine","headline":"Lundbeck inks licence option deal with Contera Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQa1hXcmtrZEJ6MXdReF9SemRVajF4MngteTBybXFISVlySEROelozMXZCVm5lY1dmdXVweVU0Ty1SSktGcU9UZHFreU51UUtCMDRKWkF2NE5lcktHZmIxalhJcXl2dE10OHpQWm1zaTd1NVN6eHIwUWszcXFrOGtENnFoaEpkaEJZQmcwUWJXeWNrZzcwVU04dDhoSENDb1pfTjFqWHpxUQ?oc=5","date":"2025-10-20","type":"pipeline","source":"The Pharma Letter","summary":"Lundbeck and Contera collaborate on RNA-targeting medicines - The Pharma Letter","headline":"Lundbeck and Contera collaborate on RNA-targeting medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5qU0FDV2QyRmRWalVGdEl2cC12VGRVajRSNVR2X05SMGNUZkdwNjJSYWhvREZpWHIzelhfTGJwazBEWG8yWWhObkhud3FiQXVWck5YRGxjTVZIOTgtdUprU24ybUdOX1pmUlJIZUh30gFyQVVfeXFMUEJlNENWRXFaZXFMcmF4NThSbnQ2UkVvT2xMZ3hsMU5KOXI5MUxZaTV3STl6SFVwVlJ3YmU4VGpXQXBSb2tUYjRUS005MUZUeFo3R0EzZU1UVjVrZ0pZdU1LSHh6NzNucWhRbkE1UnBFU1F3?oc=5","date":"2024-05-22","type":"trial","source":"koreabiomed.com","summary":"Contera Pharma announces unsuccessful P2b study for dyskinesia treatment candidate - koreabiomed.com","headline":"Contera Pharma announces unsuccessful P2b study for dyskinesia treatment candidate","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}